Due to its high prevalence and wide dissemination, breast cancer is a particularly dangerous disease. Breast cancer survival chances can be improved by early detection and diagnosis. For medical image analyzers, diagnosing is tough, time-consuming, routine, and repetitive. Medical image analysis could be a useful method for detecting such a disease. Recently, artificial intelligence technology has been utilized to help radiologists identify breast cancer more rapidly and reliably. Convolutional neural networks, among other technologies, are promising medical image recognition and classification tools. This study proposes a framework for automatic and reliable breast cancer classification based on histological and ultrasound data. The system is built on CNN and employs transfer learning technology and metaheuristic optimization. The Manta Ray Foraging Optimization (MRFO) approach is deployed to improve the framework's adaptability. Using the Breast Cancer Dataset (two classes) and the Breast Ultrasound Dataset (three-classes), eight modern pre-trained CNN architectures are examined to apply the transfer learning technique. The framework uses MRFO to improve the performance of CNN architectures by optimizing their hyperparameters. Extensive experiments have recorded performance parameters, including accuracy, AUC, precision, F1-score, sensitivity, dice, recall, IoU, and cosine similarity. The proposed framework scored 97.73% on histopathological data and 99.01% on ultrasound data in terms of accuracy. The experimental results show that the proposed framework is superior to other state-of-the-art approaches in the literature review.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454783 | PMC |
http://dx.doi.org/10.7717/peerj-cs.1054 | DOI Listing |
Breast Cancer Res
January 2025
Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Jiefang Road, Hangzhou, Zhejiang, China.
Background: Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for patients with locally advanced breast cancer (LABC), providing crucial benefits in tumor downstaging. Clinical parameters, such as molecular subtypes, influence the therapeutic impact of NACT. Moreover, severe adverse events delay the treatment process and reduce the effectiveness of therapy.
View Article and Find Full Text PDFBMC Cancer
January 2025
Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, 37 Andre Cavalcanti Street, 5th floor, Annex Building, 20231050, Rio de Janeiro, Brazil.
Background: Breast cancer (BC) has exhibited varied epidemiological trends based on distinct age categories. This research aimed to explore the incidence and mortality rates of BC within pre-defined age groups in the Brazilian population.
Methods: BC incidence trends were assessed from 2010 to 2015 using Brazilian Population-Based Cancer Registries, employing age-standardized ratios and annual average percentage change (AAPC).
BMC Med Imaging
January 2025
Electronics and Communications, Arab Academy for Science, Heliopolis, Cairo, 2033, Egypt.
Invasive breast cancer diagnosis and treatment planning require an accurate assessment of human epidermal growth factor receptor 2 (HER2) expression levels. While immunohistochemical techniques (IHC) are the gold standard for HER2 evaluation, their implementation can be resource-intensive and costly. To reduce these obstacles and expedite the procedure, we present an efficient deep-learning model that generates high-quality IHC-stained images directly from Hematoxylin and Eosin (H&E) stained images.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
University of Pittsburgh School of Medicine (Center for Clinical Genetics and Genomics), Pittsburgh, PA, USA.
Breast Cancer Res Treat
January 2025
Department of Public Health Sciences, University of Virginia, 560 Ray C Hunt Dr., Room 2107, Charlottesville, VA, USA.
Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.
Method: Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!